Cargando…

Potential Hepatotoxicity of Efavirenz and Saquinavir/Ritonavir Coadministration in Healthy Volunteers

OBJECTIVE: This study was designed to investigate the pharmacokinetic effects of coadministration of saquinavir/ritonavir with efavirenz at steady state. METHODS: Healthy volunteers in this open-label, two-arm, one-sequence, two-period crossover study (planned enrollment of 40 participants) were ran...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jamois, Candice, Riek, Myriam, Schmitt, Christophe
Formato:	Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Inc 2009
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2667896/ https://www.ncbi.nlm.nih.gov/pubmed/19381337 http://dx.doi.org/10.1111/j.1753-5174.2009.00016.x

Ejemplares similares

Unexpected Hepatotoxicity of Rifampin and Saquinavir/Ritonavir in Healthy Male Volunteers
por: Schmitt, Christophe, et al.
Publicado: (2009)

Safety and Efficacy in HIV-1-Infected Patients Treated with Ritonavir-Boosted Saquinavir Mesylate
por: Knechten, Heribert, et al.
Publicado: (2010)

Semimechanistic Modeling to Guide Venetoclax Coadministration with Ritonavir and Digoxin
por: Alhadab, Ali A., et al.
Publicado: (2020)

Substantial Effect of Efavirenz Monotherapy on Bilirubin Levels in Healthy Volunteers
por: Metzger, Ingrid F., et al.
Publicado: (2014)

Pharmacokinetic Interaction Between Prasugrel and Ritonavir in Healthy Volunteers
por: Ancrenaz, Virginie, et al.
Publicado: (2013)

Antiretroviral drugs saquinavir and ritonavir reduce inhibitory concentration values of itraconazole against Histoplasma capsulatum strains in vitro
por: Brilhante, Raimunda Sâmia Nogueira, et al.
Publicado: (2015)

Coadministration of Lopinavir/Ritonavir and Rifampicin in HIV and Tuberculosis Co-Infected Adults in South Africa
por: Murphy, Richard A., et al.
Publicado: (2012)

Efficacy, Safety and Pharmacokinetics of Once-Daily Saquinavir Soft-Gelatin Capsule/Ritonavir in Antiretroviral-Naive, HIV-Infected Patients
por: Julio, Montaner SG, et al.
Publicado: (2006)

Efavirenz and Lopinavir/Ritonavir Alter Cell Cycle Regulation in Lung Cancer
por: Marima, Rahaba, et al.
Publicado: (2020)

Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers
por: Dickinson, Laura, et al.
Publicado: (2009)

Inhibition of MMP-9 expression by ritonavir or saquinavir is associated with inactivation of the AKT/Fra-1 pathway in cervical intraepithelial neoplasia cells
por: Bacigalupo, Ilaria, et al.
Publicado: (2017)

Drug-Drug Interaction Analysis of Pyronaridine/Artesunate and Ritonavir in Healthy Volunteers
por: Morris, Carrie A., et al.
Publicado: (2012)

Correction: Coadministration of Lopinavir/Ritonavir and Rifampicin in HIV and Tuberculosis Co-Infected Adults in South Africa
por: Murphy, Richard A., et al.
Publicado: (2013)

Population Pharmacokinetics Modeling of Unbound Efavirenz, Atazanavir, and Ritonavir in HIV‐Infected Subjects With Aging Biomarkers
por: Dumond, JB, et al.
Publicado: (2016)

Clinically relevant enantiomer specific R‐ and S‐praziquantel pharmacokinetic drug‐drug interactions with efavirenz and ritonavir
por: Mutiti, Chenai Sheilla, et al.
Publicado: (2021)

Cardiac Conduction Safety during Coadministration of Artemether-Lumefantrine and Lopinavir/Ritonavir in HIV-Infected Ugandan Adults
por: Byakika-Kibwika, Pauline, et al.
Publicado: (2011)

Effects of Tipranavir, Darunavir, and Ritonavir on Platelet Function, Coagulation, and Fibrinolysis in Healthy Volunteers
por: Kort, Jens J, et al.
Publicado: (2011)

Current evidence for the risk of PR prolongation, QRS widening, QT prolongation, from lopinavir, ritonavir, atazanavir, and saquinavir: A systematic review
por: Ridjab, Denio A., et al.
Publicado: (2021)

Phase 1 Pharmacokinetic Study of AZD5718 in Healthy Volunteers: Effects of Coadministration With Rosuvastatin, Formulation and Food on Oral Bioavailability
por: Ericsson, Hans, et al.
Publicado: (2019)

New-Onset Saquinavir-Induced Diabetes
por: van Zoelen, Marieke A.D., et al.
Publicado: (2013)

Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir
por: Song, Ivy, et al.
Publicado: (2014)

Increased MMAB level in mitochondria as a novel biomarker of hepatotoxicity induced by Efavirenz
por: Tan, Zhimi, et al.
Publicado: (2017)

Amenamevir: Studies of Potential CYP3A‐Mediated Pharmacokinetic Interactions With Midazolam, Cyclosporine, and Ritonavir in Healthy Volunteers
por: Adeloye, Temitope, et al.
Publicado: (2018)

Comparison of oxidative stress markers in HIV-infected patients on efavirenz or atazanavir/ritonavir-based therapy
por: Estrada, Vicente, et al.
Publicado: (2014)

Benign elevations in serum aminotransferases and biomarkers of hepatotoxicity in healthy volunteers treated with cholestyramine
por: Singhal, Rohit, et al.
Publicado: (2014)

Tratamiento con saquinavir + zalcitabina + zidovudina vs saquinavir + lamivudina + zidovudina en pacientes con SIDA sin tratamiento previo
por: Jaimes Martínez, Marcos
Publicado: (2000)

HIV-Tat Exacerbates the Actions of Atazanavir, Efavirenz, and Ritonavir on Cardiac Ryanodine Receptor (RyR2)
por: Alomar, Fadhel A., et al.
Publicado: (2022)

Avascular Necrosis of Both Hips From Iatrogenic Cushing ’s Syndrome due to Coadministration of Fluticasone and Ritonavir in an HIV-Infected Patient
por: Kant, Ravi, et al.
Publicado: (2020)

Serum lipid profiles among patients initiating ritonavir-boosted atazanavir versus efavirenz-based regimens
por: Ganesan, Anuradha, et al.
Publicado: (2009)

Effect of a Modified Saquinavir/Ritonavir Dosing Regimen with Lower Dose Lead-In Phase on QTc Interval, Pharmacokinetics, Antiviral Activity and Safety in Treatment-Naïve HIV-1-Infected Patients
por: Boffito, Marta, et al.
Publicado: (2015)

Saquinavir: From HIV to COVID-19 and Cancer Treatment
por: Pereira, Mariana, et al.
Publicado: (2022)

Saquinavir-Piperine Eutectic Mixture: Preparation, Characterization, and Dissolution Profile
por: Fandaruff, Cinira, et al.
Publicado: (2023)

Saquinavir plus methylprednisolone ameliorates experimental acute lung injury
por: Zhang, Guanghua, et al.
Publicado: (2018)

A Case of Nephrotic Syndrome, Showing Evidence of Response to Saquinavir
por: Walters, Giles, et al.
Publicado: (2015)

Novel intravaginal nanomedicine for the targeted delivery of saquinavir to CD4(+) immune cells
por: Yang, Sidi, et al.
Publicado: (2013)

SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients
por: Kumar, P, et al.
Publicado: (2010)

Evaluation of novel Saquinavir analogs for resistance mutation compatibility and potential as an HIV-Protease inhibitor drug
por: Jayaswal, Amit, et al.
Publicado: (2014)

Enhancement of saquinavir absorption and accumulation through the formation of solid drug nanoparticles
por: Kigen, Gabriel, et al.
Publicado: (2018)

Repurposing Saquinavir for Host-Directed Therapy to Control Mycobacterium Tuberculosis Infection
por: Pires, David, et al.
Publicado: (2021)

Neutropenia after the coadministration of clozapine and nirmatrelvir-ritonavir in a patient with SARS-CoV-2 infection: A case report with a literature review
por: Liu, Chun-I, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cd4m48m86oon37pinrqdb6rtgi